Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.

Download DocumentationJuno Corporate Presentation - September 2017
Webcast ImageWebcast - Replay
Juno Therapeutics at Citi’s 12th Annual Biotech Conference
September 07, 2017 at 12:00 p.m. ET
Juno Therapeutics at Citi’s 12th Annual Biotech Conference
Thursday, September 7, 2017 12:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Juno Therapeutics at Morgan Stanley Global Healthcare Conference
September 12, 2017 at 1:30 p.m. ET
Juno Therapeutics at Morgan Stanley Global Healthcare Conference
Tuesday, September 12, 2017 1:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Recent News

DateTitle 
Sep. 21, 2017Juno Therapeutics Prices $250 Million Follow-on OfferingPrinter Friendly Version
Sep. 21, 2017Juno Therapeutics Opens New Headquarters and Research CenterPrinter Friendly Version
Sep. 20, 2017Juno Therapeutics Launches Follow-on OfferingPrinter Friendly Version
Aug. 31, 2017Juno Therapeutics to Present at September 2017 Investor ConferencesPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Past Events

DateTitle
09/12/17 1:30 p.m. ET
Juno Therapeutics at Morgan Stanley Global Healthcare Conference
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
JUNO (Common Stock)
ExchangeNASDAQ
Price$45.14
Change0.00 (0.00%)
Volume1,275
Data as of Sep. 22, 2017 4:00 p.m. ET